Skip to main content

Table 1 Patient Characteristics

From: MR radiomics predicts pathological complete response of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a multicenter study

Characters

Institution 1 (training set)

N = 82

Institution 2 (testing set)

N = 73

P-value

pCR

39 (47.5)

24 (32.9)

0.073

Age, years (median, IQR)

62 (56, 66)

62 (55, 67)

0.836

Sex

  

0.304

 Female

16 (19.6)

11 (15.1)

 

  Male

66 (80.4)

62 (84.9)

 

KPS

  

< 0.001

 ≤ 80

48 (58.5)

13 (17.8)

 

 > 80

34 (41.5)

60 (82.2)

 

Location

  

0.935

 Neck

0 (0.0)

1 (1.4)

 

 Upper thoracic

9 (11.0)

7 (9.6)

 

 Middle thoracic

29 (35.4)

28 (38.3)

 

 Lower thoracic

42 (51.2)

36 (49.3)

 

 Gastroesophageal junction

2 (2.4)

1 (1.4)

 

Length, cm (median, IQR)

5 (4.0, 6.2)

5 (4.0, 7.0)

0.461

cT

  

0.781

 1

1 (1.2)

1 (1.4)

 

 2

4 (4.9)

3 (4.1)

 

 3

53 (64.6)

53 (72.6)

 

 4

24 (29.3)

16(21.9)

 

cN

  

0.173

 0

9 (11.0)

2 (2.7)

 

 1

22 (26.8)

27 (37.0)

 

 2

42 (51.2)

36 (49.3)

 

 3

9 (11.0)

8 (11.0)

 

cM

  

0.030

 0

76 (92.7)

73 (100)

 

 1

6 (7.3)

0 (0.0)

 

Chemotherapy regimen

  

0.009

Platinum based

62 (75.6)

66 (90.4)

 

Non-platinum based

20 (24.4)

7 (9.6)

 

Radiotherapy technique

  

< 0.001

IMRT

13 (15.9)

73 (100)

 

VMAT

69 (84.1)

0 (0.0)

 

Radiation dose, Gy (median, IQR)

41.4 (37.8, 41.4)

40.0 (40.0, 40.0)

0.142

Simultaneous integrated boost

63 (76.8)

0 (0.0)

< 0.001

Interval between nCRT and surgery, days (median, IQR)

57 (48, 79)

47 (40, 52)

< 0.001

  1. Data are presented as n (%) unless otherwise stated. pCR, pathological complete response; IQR, interquartile range; KPS, Karnofsky Performance Status; cT, clinical T stage; cN, clinical N stage; cM, clinical M stage; IMRT, Intensity-Modulated Radiation Therapy; VMAT, Volumetric Modulated Arc Therapy; nCRT, neoadjuvant chemoradiotherapy